First Time Loading...

Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 11.81 USD -1.42% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

CDTX Price Targets Summary
Cidara Therapeutics Inc

Wall Street analysts forecast CDTX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDTX is 5.36 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.

CDTX Lowest Forecast
Wall Street Target
3.03 USD
74% Downside
CDTX Average Forecast
Wall Street Target
5.36 USD
55% Downside
CDTX Highest Forecast
Wall Street Target
7.35 USD
38% Downside
Lowest
Price Target
3.03 USD
74% Downside
Average
Price Target
5.36 USD
55% Downside
Highest
Price Target
7.35 USD
38% Downside
Cidara Therapeutics Inc Competitors:
Price Targets
603739
Qingdao Vland Biotech INC
5% Downside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
173% Upside
AGIO
Agios Pharmaceuticals Inc
30% Upside
H
042520
Hans Biomed Corp
175% Upside
603739
Qingdao Vland Biotech INC
5% Downside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
173% Upside
AGIO
Agios Pharmaceuticals Inc
30% Upside
H
042520
Hans Biomed Corp
175% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
ADAG
Adagene Inc
425% Upside
NGNE
Neurogene Inc
50% Upside
HARP
Harpoon Therapeutics Inc
8% Upside

Revenue
Forecast

Revenue Estimate
Cidara Therapeutics Inc

The compound annual growth rate of Cidara Therapeutics Inc's revenue for the next 3 years is -1%.

N/A
Past Growth
-1%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cidara Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cidara Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-68%
Average Miss
What are analyst estimates?

See Also

Summary
CDTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CDTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CDTX stock valuation using valuation multiples.
Wall Street Estimates
CDTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CDTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CDTX's stock price target?
Price Target
5.36 USD

According to Wall Street analysts, the average 1-year price target for CDTX is 5.36 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.

What is Cidara Therapeutics Inc's Revenue forecast?
Projected CAGR
-1%

The compound annual growth rate of Cidara Therapeutics Inc's revenue for the next 3 years is -1%.

ALPHA SPREAD
Join more than 133,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.